Pathalys Pharma, a private biopharmaceutical company in the late stages of developing treatments for kidney disease, announced it closed a $105 million Series B funding round. This oversubscribed financing was led by TCGX and joined by other notable investors including, JP Morgan Life Sciences Private Capital, Samsara BioCapital, Marshall Wace, KB Investment, JPS Growth Investment Limited Partnership, and included support from Pathalys’ founding investors, Catalys Pacific and DaVita Venture Group.
The funding raised will be utilized to finalize the two ongoing upacicalcet clinical trials, execution of the NDA filing process with the U.S. Food and Drug Administration (FDA), and acceleration of preapproval commercialization preparations. And joining the Board of Directors as members will be Dr. Chen Yu and Mr. Joe Siletto, Managing Partner of JP Morgan Life Sciences Private Capital. Plus, Dr. Roger Zhang, Ph.D. of Samsara BioCapital will join the Board as an observer.
KEY QUOTES:
“Since our inception, Pathalys has made significant strides toward our goal of delivering a best-in-class treatment for those with end-stage kidney disease (ESKD), including the near completion of two phase 3 clinical trials for upacicalcet. We believe the continued expansion of our syndicate of prominent life science investors, with representative board members, is indicative of the fact that we are on the right path at Pathalys. We are immensely grateful for the continued support of our investors and remain steadfast and confident in our mission to bring upacicalcet forward to patients.”
- Neal Fowler, Chief Executive Officer at Pathalys Pharma
“I am thrilled to support the Pathalys Pharma team in bringing upacicalcet to dialysis patients with ESKD who need improved calcimimetic treatment options. With both upacicalcet trials on track for early completion, we are hopeful that these efforts will support a near-term NDA filing with the FDA. I am excited to be a part of this journey as a member of the Pathalys board.”
- Chen Yu, M.D., Founder and Managing Partner of TCGX
“We are excited to have Chen and Joe join our Board and support Pathalys’ efforts to develop innovative medicines aimed to improve the lives of patients with kidney disease. We are confident that their extensive financial markets experience and leadership will further complement our current Board.”
• ⁃ BT Slingsby, M.D., Ph.D., M.P.H., Co-founder, and Executive Chairperson of Pathalys and Founder of Catalys Pacific
